C77-05 Incidence and Risk Factors for Pneumonitis After Check Point Inhibitor Immunotherapy in Patients With Genitourinary Cancers
F A Camacho, M C Boshkos, F Soto, S Pasyar et autres
Abstract Rationale Genitourinary cancers (GU) contribute significantly to global cancer mortality. Immune checkpoint inhibitors (ICI) have improved outcomes for patients with GU cancers. However, immune-related adverse events, including pneumonitis, can increase morbidity and mortality. Although clinical trials measure ICI-pneumonitis (ICI-P) incidence at …
us (code pays fourni par la source)